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Tailored Supramolecular Gel and Microemulsion 
Crystallization Strategies – is Isoniazid Really 
Monomorphic?† 
Stuart R. Kennedya, Christopher D. Jonesa, Dmitry S. Yufita, Catherine E. Nicholsonb, 
Sharon J. Coopera and Jonathan W. Steed*a 
 
 
 
We report the application of supramolecular gel and 
microemulsion droplet crystallisation methodologies to 
isoniazid crystallization. Tailored gelators have been designed 
with isoniazid mimetic functionality in an attempt to control 
crystal morphology and polymorphic behaviour. 
Microemulsion crystallisation was investigated to achieve 
thermodynamic control over drug crystallisation. Both 
techniques resulted in only a single form of isoniazid implying 
that it is genuinely monomorphic. 
Walter McCrone once famously stated “every compound has 
different polymorphic forms, and that, in general, the number of 
forms known for a given compound is proportional to the time and 
money spent in research on that compound”.1 This prediction is 
apparently supported by the large number of yet unobserved crystal 
forms calculated to be of similar energy to the experimentally 
isolated polymorphs in many computational crystal structure 
calculation polymorph landscapes.2 However among compounds that 
have undergone extensive polymorph screening only around 36 % 
are found to be polymorphic. This figure rises to 57 % when solvates 
are included.3 Is it the case that modern polymorph screening 
methods simply do not address the chemical space in which these 
‘missing’ solid forms can nucleate and grow, or is it true that, 
contrary to McCrone’s instinct, some compounds are always 
destined to exhibit just a single crystal form? 
 Isoniazid (or isonicotinic acid hydrazine) is a well-known 
front-line drug in the treatment of tuberculosis.4, 5 The first crystal 
structure determination of isoniazid was reported by Jensen6 who 
described the formation of needle-shaped crystals grown from 
ethanol. Further more recent redeterminations at lower temperature 
have been reported.7-9 To date isoniazid is not known to exhibit 
polymorphic behaviour.10 It does, however, form an interesting 
range of co-crystals including materials incorporating other 
pharmaceutically active substances which can improve the 
physiochemical properties of the drug or even act as a combined 
therapy.8, 10-17 This tendency to form co-crystals suggests that the 
known single–component structure of isoniazid is perhaps not 
overwhelmingly favoured and hence the monomorphic isoniazid 
represents an interesting target for unconventional crystallization 
methodologies.  
 The use of low molecular weight gels (LMWG) as media 
to template or influence crystal growth is a potentially powerful new 
method for polymorph screening and crystal morphology 
modification.18-25 Gelators can be designed to form gels in a variety 
of solvent systems and the reversibility of gelation by small 
molecules offers a convenient way to isolate gel-grown 
pharmaceutical crystals. There are numerous examples of 
compounds acting as LMWG such as fatty acids, steroids, anthryl 
derivatives, amino acids or metal-based gels.26-33 Among the most 
versatile are urea-based gelators due to the relative ease of designing 
and synthesising tailor-made gelators with targeted solubility and 
chemical functionality than can complement a particular drug 
functional group or fragment.20, 34 Bis(urea) gelators are relatively 
simple to prepare from the reaction of an isocyanate with an amine 
allowing facile access to a wide range of bis and tris(urea)s with a 
variety of spacers and functional groups.35-37 Recently we have 
demonstrated how LMWG can be used for pharmaceutical crystal 
growth by designing molecules with both gel forming attributes and 
either generic or drug mimetic functionality. Careful consideration 
of both solvent and gelator has been shown to yield differing crystal 
forms of the same drug molecule.18, 20 Gels with drug-mimetic 
functionality offer the possibility of significant interactions between 
drug and gel fibre surface and even epitaxial overgrowth of the drug 
crystal on the gel parent. Unusual gels such as a nanocellulose 
organogel have also revealed previously unknown solid forms.22 
In addition to gel methodologies, an emerging 
crystallization technique is crystallization in microemulsion 
droplets.38-41 Microemulsion crystallisation allows for 
thermodynamic control over crystallisation outcome, essentially 
‘leapfrogging’ Ostwald’s rule of stages.41 Between them, 
supramolecular gels and microemulsions offer the possibility of 
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significantly expanding polymorph discovery space with the locally 
order gel fibre surface offering the possibility of epitaxial 
overgrowth of hard-to-nucleate metastable polymorphs, while the 
microemulsion approach ‘zeroes-in’ on the thermodynamic form. 
In the present work we report a tailored supramolecular gel 
phase approach to search for isoniazid polymorphs and compare the 
outcome to the microemulsion method and to conventional solution 
crystallization which has been known to give rise to just one pure 
form of isoniazid since 1954.6 
 
Gelator design and synthesis 
Hydrogelators bearing an isoniazid-derived functionality have 
previously been reported,42 but have not been studied in a 
pharmaceutical crystallization context. Synthesis of the isoniazid-
mimetic gelators 1 and 2 (Figure 1) was carried out in good yield by 
the relatively straightforward one-pot reaction between isoniazid and 
the desired isocyanate (see experimental section). The 
diphenylmethane derived spacer in compound 1 commonly results in 
highly effective gelation behaviour in bis(urea)s, while the sterically 
confined spacer in 2 tends to result in a mixture of crystalline and 
gel-forming behaviour.43, 44   
 
 
Figure 1. Molecular structures of isoniazid and isoniazid-mimetic 
gelators 1 and 2. 
 
Gelation 
Compounds 1 and 2 were screened for gelation behaviour in a range 
of common solvents. All gelation tests were carried out at 1 % w/v 
by heating a sample (5 mg) suspended in the desired solvent (0.5 
mL) followed by sonication45 for 60 seconds. Gelation experiments 
of compound 1 were carried out in 51 solvents (Table S1, 
supplementary information). The gelator dissolved in 27 of these 51 
solvents and gels formed in 19 of these 27 samples. In 10 of these 
gelled samples were opaque while the remaining 9 gave more 
transparent gels. In most cases gelation occurs rapidly and the 
mixture forms gels prior to the end of the sonication cycle. A 
selection of the transparent gels was dried by allowing the solvent to 
slowly evaporate over two days and the resulting xerogels imaged 
using SEM (Figure 2). The SEM micrographs of the xerogels of 1 
from various solvents show that there is a fibrous network present 
and in some cases helical fibres are observed (Figure 2a). Compound 
2 proved to be a non-gelator but was soluble in 34 of the 51 solvents 
tested and crystallized from six of them (vide infra). 
 
 
Figure 2. SEM images of xerogels of compound 1. a) Dried dimethyl 
formamide gel showing helical fibres. b) Fibrous network from 
dimethyl acetamide showing the relatively long length of some of 
the individual fibres. In both cases the gels investigated were 
transparent where the samples were air dried for two days and coated 
with 3 nm of chromium. 
 
Gel phase crystallisation of isoniazid 
Crystallization tests were carried out for isoniazid in the 19 solvents 
in which gels were obtained for gelator 1 using a 1 wt% isoniazid. 
The drug substance and gelator were warmed to give a solution and 
then allowed to cool on the benchtop resulting in gelation over 
periods of 1 – 24 h. Crystallization had occurred in a total of eight 
samples after one week in the sealed vials at room temperature. All 
eight samples proved to be the known polymorph of isoniazid. In six 
of the eight cases the crystals adopted the same needle-shaped 
morphology as the material from solution control experiments. Some 
differences were observed for nitrobenzene and propan-1-ol, 
however. When isoniazid was introduced to a nitrobenzene solution 
containing gelator 1 and allowed to gel, crystal growth proved to be 
significantly slower than in a solution control experiment without 
gelator under the same conditions and there was no evidence of 
crystalline material after a few hours. Over 48 hours however, a 
single large plate-shaped crystal appeared, consistent with the 
reduced nucleation and convection within the gel (Figure 3). 
Interestingly, after 96 hours the typically very stable nitrobenzene 
gel of 1 had collapsed. It is evident that the presence of isoniazid 
within this gel seems to affect its stability. This slow reversal of the 
gelation process is potentially advantageous as it allows for the easy 
removal of the crystal without the need of potentially damaging it 
using other removal techniques (e.g. the introduction of competitor 
species such as anions to dissolve the gel).18, 46, 47 An additional 
benefit of this ‘collapsing’ gel is the potential to recycle the gelator 
to undertake further crystal growth in the same sample by removing 
isoniazid crystals by filtration and subsequently thermally 
reinitiating the gel formation process in the presence of further drug. 
Single crystal X-ray diffraction experiments carried out on the gel-
grown isoniazid crystal showed it is also the previously reported 
polymorph despite its different morphology.6-8 
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Figure 3. a) Single sample-spanning isoniazid crystal obtained after 
the collapse of a nitrobenzene gel of 1. b) Relatively small needle-
shaped crystals of isoniazid obtained from nitrobenzene in the 
absence of gel. 
 
Using gels as crystal growth media not only has the potential to 
affect crystal size but can also alter crystal morphology. Isoniazid 
itself does not crystallise from propan-1-ol however, when isoniazid 
was introduced into a 1 wt% sample of propan-1-ol containing the 
gelator 1, the formation of crystalline material was observed after 1 
week. The crystals adopted a small block-shaped morphology 
(Figure 4). Again this material proved to be the known polymorph of 
isoniazid.6-8 
 
 
Figure 4. a) Typical needle-shaped isoniazid crystals grown from 
methanol. b) Isoniazid crystals grown in a propan-1-ol gel of 1 
showing a clear change in crystal habit. Isoniazid does not crystallize 
from propan-1-ol in the absence of gel. 
 
Microemulsion crystallisation of isoniazid 
Crystallization in microemulsion droplets leads to thermodynamic 
control under supersaturation conditions where crystallization is only 
just achievable. At supersaturations below this, the supersaturated 
system is stabilised due to the nanoconfinement and at 
supersaturations significantly above this, the crystallization reverts to 
the kinetic control typically observed in bulk systems.39-41 Since both 
conventional crystallization and gel-phase experiments result only in 
a single solid form of isoniazid, microemulsion crystallization 
represents a way to further test whether this form is highly 
kinetically favoured or whether it does indeed represent a 
‘thermodynamic sink’. In each microemulsion experiment, 2 × 2 g 
aliquots of sodium dioctyl sulfosuccinate (AOT) solutions in heptane 
at 3, 10, 20 and 25% AOT by mass were combined with 25 µl or 100 
µl of a 38 mg mL-1 aqueous solution of isoniazid using a 
micropippete.  The microemulsions were shaken by hand to form an 
optically transparent single phase and held at 21 °C. Isoniazid is 
undersaturated in bulk aqueous solutions at 38 mg mL-1 but becomes 
supersaturated in the microemulsion droplet core due to preferential 
water adsorption at the surfactant interface.  
In the microemulsions containing 100 L isoniazid 
solution, needle-shaped crystals were obtained after 3 days in all 
systems. Needles were also obtained after 3 days in the 3 and 10% 
AOT microemulsions containing 25 L isoniazid solution. In all 
cases, XRD and melting point data established that the crystals were 
the known form of isoniazid. No crystallization occurred for the 
smaller droplet microemulsions containing 20 and 25% AOT and 25 
L isoniazid solution, even after one year. The smaller the droplet 
size, the higher the supersaturation required to achieve crystallisation 
because the supersaturation is rapidly depleted as the crystal nucleus 
grows. Hence, these systems were stabilised due to nanoconfinement 
because this supersaturation threshold was not achieved. The 
microemulsions chosen spanned a range of sizes from too small for 
crystallization to occur (25 L isoniazid solution in 20 and 25% 
AOT solution) to larger droplet sizes (100 L isoniazid solution in 3 
and 10% AOT solution) where kinetic forms would crystallize. The 
fact that all microemulsions that were capable of forming crystals 
yielded the known form reinforces the hypothesis that isoniazid is 
monomorphic. 
  
Solid state chemistry of compound 2 
While the relatively bulky spacer in 2 limits its ability to form 
hydrogen bonded tapes, and hence form gels. As a result its higher 
crystallinity allows the characterisation of a number of solvates that 
collectively give insight into the intermolecular interactions in the 
gels. Crystallization of 2 from six different solvent systems by slow 
cooling followed by slow evaporation of the cooled solution resulted 
in a non-solvated form and five solvates with water, propan-2-ol, 
butan-1-ol, cyclohexanone and 4-ethylpyridine which were all 
characterised by X-ray crystallography. 
 
Non-solvated structure of 2 
Crystals of 2 grown from propan-1-ol proved to be non-solvated and 
adopt a high symmetry tetragonal cell with the space group I4̅2d. 
The asymmetric unit comprises one half molecule of 2 (Z' = 0.548). A 
combination of the sterically demanding spacer and competing 
hydrogen bonding interactions, prevent urea tape formation (Figure 
5). The NH groups from the isoniazid mimetic part of 2 results in the 
formation of a type I hydrogen-bonded synthon (Figure 6) involving 
a combination of a 𝑹𝟐
𝟐(10) hydrogen bonded ring and the urea-
pyridine 𝑹𝟐
𝟏(6) synthon.49, 50 The 𝑹𝟐
𝟐(10) motif takes advantage of 
the less sterically hindered side of the carbonyl acceptor and might 
potentially allow hydrogen bonded tape aggregation and hence 
gelation, the chain is truncated by the 𝑹𝟐
𝟏(6) pyridyl interaction 
which is not typical in gels50 and likely inhibits fibre formation.34  
 
Solvate structures of 2 
Solvate structures of 2 with water, propan-2-ol, butan-1-ol and 
cyclohexanone were also characterised by X-ray crystallography. In 
the monohydrate structure 2·H2O the crystals form a conglomerate51 
in the Sohnke space group P212121 with Z' = 1 despite the achirality 
of the molecule. The propan-2-ol structure is a centrosymmetric 
disolvate of 2· in Pbca with Z' = 1. The cyclohexanone disolvate is 
also centrosymmetric, 2·2 cyclohexanone P21/c with Z' = 2. Finally, 
the 2-butanol monosolvate (2·butan-1-ol) is a more unusual Z′ = 4 in 
P𝟏.  
In all four solvated structures the urea -tape that is 
generally thought to be responsible for gel formation52, 53 is sterically 
unfavourable and is replaced by varying types of alternative 
hydrogen bonding synthons. For 2·H2O, the water molecule non-
covalently bridges together the carbonyl group of the isoniazid-
derived part of the molecule with a urea NH proton thereby 
preventing fibre and subsequent gel formation (Figure 7). 
Additionally, the formation of a NH•••N pyridyl-urea hydrogen-
bonded synthon at the other urea group and the formation of an 
𝑹𝟐
𝟐(10) synthon between the drug mimetic part of one molecule and 
a urea carbonyl of another molecule, further inhibit urea tape 
formation (Type II hydrogen bonding motif, Figure 6). 
 
a) b) 
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Figure 5. a) Molecular structure of 2. b) Type I hydrogen bonding 
synthon observed in the extended structure of 2. CH hydrogen atoms 
omitted for clarity.  
 
 
Figure 6. Hydrogen-bonded synthons observed in the solvated and 
non-solvated crystal structures of 2. Type I comprises both a 𝑹𝟐
𝟏(6) 
NH•••N pyridyl-urea hydrogen-bonded synthon and a 𝑹𝟐
𝟐(10) 
NH•••O urea-isoniazid mimetic hydrogen-bonded synthon. Type II 
comprises both a pyridyl hydrogen bonding to a single urea proton 
and a 𝑹𝟐
𝟐(10) NH•••O urea-isoniazid mimetic hydrogen-bonded 
synthon. Type III intramolecular formation of a 𝑺𝟐
𝟏(6) NH•••O urea-
carbonyl hydrogen-bonded synthon. Type IV intramolecular 
formation of a 𝑺𝟐
𝟏(6) NH•••O urea-carbonyl hydrogen-bonded 
synthon along with a NH•••N urea-pyridyl hydrogen-bonded 
synthon. 
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Figure 7. The asymmetric unit of 2·H2O showing the water molecule 
bridging the isoniazid mimetic part of 2 with a urea NH group. CH 
hydrogen atoms are omitted for clarity.  
 
In the crystal structure of 2·2 propan-2-ol an 𝑺𝟐
𝟏(6) hydrogen-bonded 
synthon between the carbonyl of the drug mimetic part of 2 and a 
urea group prevent α-tape formation (Type III hydrogen bonding 
motif), Figure 8. Additional NH•••O urea-carbonyl intramolecular 
and NH•••O intermolecular hydrogen bonding interactions further 
disrupts urea-tape formation. Unlike the Type I and Type II 
hydrogen-bonded synthons, there are no pyridyl-urea interactions in 
2·2 propan-2-ol due the presence OH•••N pyridyl-solvent 
interactions. 
 
 
Figure 8. Part of the asymmetric unit of 2·2 propan-2-ol showing the 
intramolecular hydrogen bonded folding of the molecule. CH 
hydrogen atoms are omitted for clarity. 
 
The crystal structure of 2·2 cyclohexanone is based on type III 
hydrogen bonding synthons (Figure 6). A cyclohexanone molecule 
bridges the urea groups via NH•••O urea-solvent hydrogen bonding 
interactions as an alternative to urea tape formation (Figure 9). 
Intramolecular NH•••O interactions are present between a urea 
hydrogen atom and the carbonyl of the isoniazid mimetic part of the 
molecule. The presence of 𝑹𝟐
𝟐(10) hydrogen bonding interactions 
between the NH group on the drug mimetic region and urea carbonyl 
groups also replace urea tape formation.  
 
Figure 9. Part of the asymmetric unit of 2·2 cyclohexanone showing 
both intramolecular and solvent hydrogen bonding. CH hydrogen 
atoms are omitted for clarity. 
 
The crystals of 2·butan-1-ol, were found to be weakly diffracting 
and the structure was determined using synchrotron radiation at the 
I19 facility at Diamond, UK. Disorder is present in two solvent 
molecules and one of the molecules of 2. In three of the 
crystallographically independent molecules of 2, the urea groups 
form a type IV hydrogen-bonding synthon to give a supramolecular 
dimer (Figure 10).  Assembly of the dimer is via 𝑺𝟐
𝟏(6) NH···O urea-
carbonyl and NH···N urea-pyridyl hydrogen-bonded synthons along 
with a π-stacking interaction between the isoniazid mimetic tails. 
The fourth independent molecule of 2 forms a type III hydrogen-
bonded synthon. 
 
Figure 10. Illustration of part of the Z′ = 4 asymmetric unit observed 
in 2·butan-1-ol showing intramolecular and intermolecular hydrogen 
bonding interactions. The π-stacking interaction present in the dimer 
COMMUNICATION Journal Name 
6 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 2012 
is highlighted as a yellow dashed line. Hydrogen atoms except those 
involved in hydrogen bonding interactions are omitted for clarity. 
 
Drug-like co-crystallisation of 2 with 4-Ethylpyridine 
While there have been a number of reports of drug substances 
crystallized in small-molecule gels,18-24, 34, 54 it is perhaps 
surprisingly that there have been no reports of drug-gelator co-
crystals. The main reason for this paucity is likely to be time-
resolved self-sorting in which gelation by gelator aggregation occurs 
more quickly than the formation of any putative cocrystals. While 
such self-sorting is important in the application of LMWG to drug 
crystallization, structural characterisation of a gelator-drug cocrystal 
would give useful insight into the way in which a drug may interact 
with a gel surface and hence allow for a greater understanding of the 
drug-gelator interactions which may be the beginnings of drug 
crystal nucleation in supramolecular gels. In order to obtain such 
structural insight we investigated different crystallisation techniques 
with a view to forming a co-crystal of 2 with isoniazid and with the 
related pharmaceutical compounds 4-aminopyridine and the liquid 
drug-like model compound 4-ethylpyridine. Co-crystallization was 
attempted by melting isoniazid, adding varying amounts of 2 and 
allowing the melt to cool to room temperature. However single 
crystal analysis on a number of samples showed that only the known 
form of isoniazid was isolated. Co-crystallization with 
4-aminopyridine was similarly unsuccessful. However, 1:1 
cocrystals of 2 with 4-ethylpyridine were obtained by allowing a hot 
solution of 2 in 4-ethylpyridine (m.p. 2.4 oC) to cool to room 
temperature. The asymmetric unit comprises two molecules of 2 and 
two molecules of 4-ethylpyridine. The structure comprises 𝑺𝟐
𝟏(6) 
NH···O urea-carbonyl hydrogen bonding interactions (type IV 
hydrogen-bonded synthon, Figure 6). The structure also incorporates 
𝑹𝟐
𝟐(10) NH···O hydrogen bonding interactions between the isoniazid 
mimetic NH group and urea carbonyl group and as in the other 
structures of 2, no urea -tape 𝑹𝟐
𝟏(6) type interactions are observed 
(Figure 11). Several molecules of 2 encapsulate two molecules of 4-
ethylpyridine completely isolating the guest molecules from other 
solvent (Figure 12). The ethylpyridine guests interact with molecule 
of 2 only via weak CH···N hydrogen bond from the host pyridyl CH 
groups. This process is reminiscent of gel-like characteristics where 
the solid network of 2 traps the solvent molecules rendering them 
immobile. Experiments were carried out in an attempt to replace the 
4-ethylpyridine with isoniazid. A series of crystallisation 
experiments with varying concentrations of isoniazid in a 1 wt. % 
solution of 2 in 4-ethylpyridine were investigated however only 
crystals of 2·4-ethylpyridine resulted.  
 
Figure 11. Hydrogen bonding interactions observed between 
neighbouring molecules of 2 in the asymmetric unit of 2·4-
ethylpridine. The yellow dashed line highlights a π-stacking 
interaction. Solvent molecules and hydrogen atoms not involved in 
hydrogen bonding interactions are omitted for clarity. 
 
 
Figure 12. a) Partial space filling representation of encapsulated 4-
ethylpyridine guest molecules in 2·4-ethylpridine. Guest molecules 
are highlighted as space filling representation. All hydrogen atoms 
are omitted for clarity except for those on the highlighted guest 
molecules. b) Crystal packing in 2·4-ethylpridine. Molecules of 2 are 
shown in blue and pairs of 4-ethylpyridine molecules are highlighted 
in either red and yellow space filling representation showing their 
isolation. 
Conclusion 
We have shown that it is possible to design a tailored gelator 
for isoniazid through a relatively simple one step synthetic 
procedure. Gel phase crystallisation of isoniazid versus solution 
phase crystallisation produces some significant differences in 
crystal habit and crystal size. Crystals can also be grown in a 
gel based on a solvent that typically does not produce any 
crystalline material. In one case crystallization is conveniently 
accompanied by gel collapse, facilitating crystal recovery. 
Despite these differences, both supramolecular gel and 
microemulsion crystallization methods give rise to the one 
known polymorph of isoniazid that is also obtained from 
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solution, reinforcing the view that this compound only 
crystallises in one non-solvated polymorphic form. The 
sterically hindered isoniazid derivative 2 does not form gels. Its 
various crystal structures give an insight into the factors which 
prevent gelation as a result of competing hydrogen bonding 
interactions and steric interference from the bulky spacer group. 
The 2·4-ethylpyridine co-crystal structure is interesting from 
the point of view of building insight into the aggregation of 
drug-like molecule close to the surface of LMWGs. While this 
work has not expanded the experimental solid form landscape 
of isoniazid, this combined gel and microemulsion strategy 
represents a potentially powerful polymorph discovery tool in 
less well explored and potentially polymorphic systems. 
 
Experimental 
 
Synthesis 
Compound 1: Isoniazid (0.5 g, 3.65 mmol) was added to a 
solution of 4,4-methylenebis(2,6-diethylaniline) (0.66 g, 1.82 
mmol) in chloroform:ethanol (15 mL:1.5 mL) and triethylamine 
(1 mL, 7.17 mmol) to give a solution that was heated under 
reflux for 24 h. A precipitated formed which was filtered and 
washed with CHCl3 to give 1 as a white solid (0.98 g, 1.54 
mmol, 84%). 1H NMR (400 MHz, DMSO-d6) δ 10.56 (s, 2H, 
NH), 8.78 – 8.69 (m, 4H, ArH), 8.20 (s, 2H, NH), 7.98 (s, 2H, 
NH), 7.83 (d, 3J = 5.1 Hz, 4H, ArH), 6.94 (s, 4H, ArH), 3.84 (d, 
J = 6.1 Hz, 2H, CH2), 2.57 – 2.46 (m, 8H, CH2CH3), 1.07 (d, J 
= 7.4 Hz, 12H, CH2CH3); 13C{1H} NMR (400 MHz, DMSO-d6) 
δ 165.38 (C=O), 150.47 (ArC), 142.42 (ArC), 140.16 (ArC), 
132.18 (ArC), 126.38 (ArC), 121.94 (ArC), 46.13 (CH2), 24.68 
(CH2CH3), 15.35 (CH2CH3). ESI-MS M+H+ m/z 637.8. 
 
Compound 2: Isoniazid (0.51 g, 3.72 mmol) was added to a 
solution of 1,3-bis(1-isocyanato-1-methylethyl)benzene (0.42 
mL, 1.82 mmol) in chloroform:ethanol (15 mL:1.5 mL). and 
triethylamine (1 mL, 7.17 mmol) to give a solution that was 
heated under reflux for 24 h. A precipitated formed which was 
filtered and washed with CHCl3 to give 2 as a white solid (0.92 
g, 1.77 mmol, 95%) 1H NMR (400 MHz, DMSO-d6) δ 10.46 (d, 
3J = 2.8 Hz, 2H, NH), 8.76 – 8.70 (m, 4H, ArH), 7.92 (d, 3J = 
2.8 Hz, 2H, NH), 7.80 – 7.73 (m, 4H, ArH), 7.44 (q, 3J = 1.4 
Hz, 1H, ArH), 7.25 – 7.18 (m, 3H, ArH), 6.77 (s, 2H, NH), 1.59 
(s, 12H, CH3); 13C{1H} NMR (400 MHz, DMSO-d6) δ 165.14 
(C=O), 157.22 (C=O), 150.73 (ArC), 148.23 (ArC), 140.08 
(ArC), 127.74 (ArC), 122.94 (ArC), 121.75 (ArC), 55.31 
(CCH3), 30.44 (CCH3). ESI-MS M–H+ m/z 517.2. 
 
Scanning Electron Microscopy 
SEM samples were dried in air at room temperature for 2 days, 
coated with 3 nm of chromium using a Cressington 328 Ultra High 
Resolution EM Coating System, and imaged using an FEI Helios 
NanoLab DualBeam microscope in immersion mode, with typical 
beam settings of 1.5 kV and 0.17 nA. 
  
Single crystal X-ray diffraction 
Single crystal data for 2, 2·H2O, 2·2 propan-2-ol, 2·2 
cyclohexanone were collected at 120.0(2) K on a Bruker 
D8Venture diffractometer (PHOTON-100 CMOS detector, 
IμS-microsource, focusing mirrors, MoKα, λ = 0.71073Å) and 
processed using Bruker APEX-II software. The temperature of 
the samples was maintained by the Cryostream (Oxford 
Cryosystems) open-flow nitrogen cryostat. The data for 
2_butanol and 2·4-ethylpyridine were collected at 120K on a 
Rigaku Saturn 724+ diffractometer at station I19 of the 
Diamond Light Source synchrotron (undulator,  = 0.6889 Å, 
-scan, 1.0°/frame) and processed using Bruker APEXII 
software. 
 
Crystals of 2 were prepared by allowing a propan-1-ol solution of 
the sample to slowly evaporate. Crystal data for 2, C26H30N8O4, M = 
518.58, 0.35  0.27  0.15 mm3, tetragonal, space group I4̅2d (No. 
122), a =  b = 15.8133(5), c = 20.5773(8) Å, V = 5145.6(4) Å3, Z = 
8, Dc = 1.339 g/cm3,  = 0.094 mm-1, F000 = 2192, 41617 reflections 
collected, 3749 unique (Rint = 0.0416).  Final GOOF = 1.040, R1 = 
0.0329 (3480 reflections with I >2σ(I)), wR2 = 0.0814,  (all data, 
refinement on F2), 233 parameters, 0 restraints.   
 
Crystals of 2·H2O were prepared by allowing a water solution 
of the sample to slowly evaporate. Crystal data for 2·H2O, 
C26H32N8O5, M = 536.60, 0.094  0.161  0.218 mm3, 
orthorhombic, space group P212121 (No. 19), a = 9.0337(7), b = 
14.7317(14), c = 19.8607(15) Å, V = 2643.1(4) Å3, Z = 4, Dc = 
1.355 g/cm3, = 0.097 mm-1 F000 = 1136, 27044 reflections 
collected, 7018 unique (Rint = 0.1001).  Final GOOF = 1.020, 
R1 = 0.0723 (5290 reflections with I >2σ(I)), wR2 = 0.1782,  (all 
data, refinement on F2), 359 parameters, 0 restraints.  
 
Crystals of 2·2 propan-2-ol were prepared by allowing a 
propan-2-ol solution of the sample to slowly evaporate. Crystal 
data for 2·2 propan-2-ol, C32H44N8O6, M = 636.75, 0.105  
0.145  1.016 mm3, orthorhombic, space group Pbca (No. 61), 
a = 17306(2), b = 16.8727(19), c = 23.268(3) Å, V = 
6794.3(15) Å3, Z = 8, Dc = 1.245 g/cm3,  = 0.088 mm-1, F000 = 
2720, 57136 reflections collected, 7413 unique (Rint = 0.2469).  
Final GOOF = 1.015, R1 = 0.0868 (3777 reflections with I 
>2σ(I)), wR2 = 0.2169,  (all data, refinement on F2), 425 
parameters, 0 restraints.   
 
Crystals of 2·4-ethylpyridine were prepared by allowing a 4-
ethylpyridine solution of the sample to slowly evaporate. 
Crystal data for 2·4-ethylpyridine, C66H78N18O8, M = 625.73, 
0.398  0.081  0.060 mm3, triclinic, space group P-1 (No. 2), 
a = 13.3968(8), b = 16.0797(6), c = 16.7219(8) Å, = 
84.489(4), = 67.608(5), = 82.921(4)°, V = 3300.5(3) Å3, Z = 
2, Dc = 1.259 g/cm3,  = 0.088 mm-1 ,F000 = 1328, 37133 
reflections collected, 17743 unique (Rint = 0.0535). Final GOOF 
= 1.035, R1 = 0.0603 (12650 reflections with I >2σ(I)), wR2 = 
0.2320,  (all data, refinement on F2), 842 parameters,  0 
restraints.  
 
Crystals of 2·2 cyclohexanone were prepared by allowing a 
cyclohexanone solution of the sample to slowly evaporate. 
Crystal data for 2·2 cyclohexanone: C38H50N8O6, M = 1429.72, 
0.30  0.16  0.12 mm3, monoclinic, space group P21/c (No. 
14), a = 16.641(3), b = 16.911(3), c = 26.532(4) Å, = 
92.145(5)°, V = 7461(2) Å3, Z = 8, Dc = 1.273 g/cm3,  = 0.089 
mm-1, F000 = 3056, 660605 reflections collected, 14706 unique 
(Rint = 0.1263).  Final GOOF = 1.164, R1 = 0.1197 (7681 
reflections with I >2σ(I)), wR2 = 0.2607  (all data, refinement 
on F2), 946 parameters, 0 restraints.   
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